Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Erastin synergizes with cisplatin via ferroptosis to inhibit ovarian cancer growth in vitro and in vivo
Qi Cheng, Lingjie Bao, Ming‐Qing Li, et al.
Journal of Obstetrics and Gynaecology Research (2021) Vol. 47, Iss. 7, pp. 2481-2491
Closed Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Overcoming cancer chemotherapy resistance by the induction of ferroptosis
Yumin Wang, Xiaorui Wu, Ren Zhao, et al.
Drug Resistance Updates (2022) Vol. 66, pp. 100916-100916
Closed Access | Times Cited: 163
The emerging role of ferroptosis in female reproductive disorders
Min Liu, WU Ke-ming, Yeke Wu
Biomedicine & Pharmacotherapy (2023) Vol. 166, pp. 115415-115415
Open Access | Times Cited: 42
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives
Chenliang Zhang, Tingting Huang, Liping Li
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 16
Metabolic regulation of ferroptosis in the tumor microenvironment
Nneka E. Mbah, Costas A. Lyssiotis
Journal of Biological Chemistry (2022) Vol. 298, Iss. 3, pp. 101617-101617
Open Access | Times Cited: 67
Ferroptosis, necroptosis, and pyroptosis in the occurrence and development of ovarian cancer
Chunmei Zhang, Ning Liu
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 55
Targeting Ferroptosis Pathway to Combat Therapy Resistance and Metastasis of Cancer
Xuan Liu, Yiqian Zhang, Xuyi Wu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 44
Doxorubicin and erastin co-loaded hydroxyethyl starch-polycaprolactone nanoparticles for synergistic cancer therapy
Xu Chen, Shiyou Li, Jitang Chen, et al.
Journal of Controlled Release (2023) Vol. 356, pp. 256-271
Closed Access | Times Cited: 41
Evaluation of erastin synergized cisplatin anti-nasopharyngeal carcinoma effect with a glutathione-activated near-infrared fluorescent probe
Rong He, Dandan Tang, Ningge Xu, et al.
Chinese Chemical Letters (2023) Vol. 35, Iss. 2, pp. 108658-108658
Closed Access | Times Cited: 29
Ferroptosis and immunosenescence in colorectal cancer
Yao Wang, Xinran Cao, Chunbaixue Yang, et al.
Seminars in Cancer Biology (2024) Vol. 106-107, pp. 156-165
Closed Access | Times Cited: 10
Lipid peroxidation of immune cells in cancer
Liuling Xiao, Miao Xian, Chuanchao Zhang, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 9
Ferroptosis and EMT resistance in cancer: a comprehensive review of the interplay
Huiming Zhang, Naifeng Chen, Chenglong Ding, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 8
Ferroptosis and cuproptosis: Metal-dependent cell death pathways activated in response to classical chemotherapy – Significance for cancer treatment?
Mateusz Kciuk, Adrianna Gielecińska, Żaneta Kałuzińska‐Kołat, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 4, pp. 189124-189124
Open Access | Times Cited: 8
Ferroptosis in Cancer Therapy: Mechanisms, Small Molecule Inducers, and Novel Approaches
YiLin Luo, Xin Yue Bai, L.J. Zhang, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 2485-2529
Open Access | Times Cited: 8
Ferroptosis and Tumor Drug Resistance: Current Status and Major Challenges
Zhenyu Nie, Mei Chen, Yuanhui Gao, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 35
Ferroptosis in tumor immunity and therapy
Chuandong Gong, Qiankun Ji, Miaojing Wu, et al.
Journal of Cellular and Molecular Medicine (2022) Vol. 26, Iss. 22, pp. 5565-5579
Open Access | Times Cited: 31
CRISPR/Cas9-mediated knockout of Lcn2 in human breast cancer cell line MDA-MB-231 ameliorates erastin-mediated ferroptosis and increases cisplatin vulnerability
Mehdi Rabiee Valashedi, Amaneh Mohammadi Roushandeh, Kazuo Tomita, et al.
Life Sciences (2022) Vol. 304, pp. 120704-120704
Closed Access | Times Cited: 29
Ferroptosis is an effective strategy for cancer therapy
Afrasyab Khan, Yu Huo, Yilei Guo, et al.
Medical Oncology (2024) Vol. 41, Iss. 5
Closed Access | Times Cited: 7
The Role of ROS as a Double-Edged Sword in (In)Fertility: The Impact of Cancer Treatment
Sara Mendes, Rosália Sá, Manuel Ferreira‐Magalhães, et al.
Cancers (2022) Vol. 14, Iss. 6, pp. 1585-1585
Open Access | Times Cited: 24
Ferroptosis: a dual-edged sword in tumour growth
Xiangye Zhao, Xiaoning Li, Yinghui Xu
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 5
Ferroptosis-Inducing Nanomedicine for Cancer Therapy
Yang Wang, Tianfu Liu, Xiang Li, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 32
Integrated Analysis of Ferroptosis-Related Biomarker Signatures to Improve the Diagnosis and Prognosis Prediction of Ovarian Cancer
Huan Wang, Qi Cheng, Kai‐Kai Chang, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 9
Open Access | Times Cited: 22
Ferroptosis: A New Promising Target for Ovarian Cancer Therapy
Hongjiang Zhao, Yuan Xu, Hongkai Shang
International Journal of Medical Sciences (2022) Vol. 19, Iss. 13, pp. 1847-1855
Open Access | Times Cited: 22
Ferroptosis as an emerging therapeutic target in liver diseases
Yuzhen Lu, Junjie Hu, Liang Chen, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 11
Ferroptosis Inducers Erastin and RSL3 Enhance Adriamycin and Topotecan Sensitivity in ABCB1/ABCG2-Expressing Tumor Cells
L. Perera, Shalyn M. Brown, Brian B. Silver, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 635-635
Open Access
Metabolic consequences of erastin-induced ferroptosis in human ovarian cancer cells: an untargeted metabolomics study
Kaylie I. Kirkwood‐Donelson, Alan K. Jarmusch, Carl D. Bortner, et al.
Frontiers in Molecular Biosciences (2025) Vol. 11
Open Access
Page 1 - Next Page

Scroll to top